Spots Global Cancer Trial Database for car t cells
Every month we try and update this database with for car t cells cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Malignant Pleural Disease Treated With Autologous T Cells Genetically Engineered to Target the Cancer-Cell Surface Antigen Mesothelin | NCT02414269 | Malignant Pleur... Mesothelioma Metastases Lung Cancer Breast Cancer | iCasp9M28z T ce... cyclophosphamid... pembrolizumab | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (TRANSCEND-NHL-001) | NCT02631044 | Non-Hodgkin Lym... Diffuse Large B... Follicular Lymp... Mantle-cell Lym... Primary Mediast... | JCAR017 (lisoca... JCAR017 (lisoca... | 18 Years - | Juno Therapeutics, a Subsidiary of Celgene | |
| Study of CAR-T Cells Expressing CD30 and CCR4 for r/r CD30+ HL and CTCL | NCT03602157 | Lymphoma Immune System D... Immunoprolifera... Lymphatic Disea... Lymphoprolifera... Neoplasms Cutaneous Lymph... Cutaneous Anapl... Mycosis Fungoid... Sezary Syndrome Lymphomatoid Pa... Cutaneous T Cel... Gray Zone Lymph... | ATLCAR.CD30.CCR... ALTCAR.CD30 cel... Bendamustine Fludarabine | 18 Years - | UNC Lineberger Comprehensive Cancer Center | |
| Efficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma Patients | NCT04844866 | Diffuse Large B... | MB-CART2019.1 R-GemOx or BR p... | 18 Years - | Miltenyi Biomedicine GmbH | |
| CAR T Cells in Treating Patients With Malignant Gliomas Overexpressing EGFR | NCT02331693 | Advanced Glioma | anti-EGFR CAR T | 18 Years - 70 Years | RenJi Hospital | |
| A Retrospective Study of Patients With Leukemia Relapse in the CNS Treated With CAR T Cells | NCT04158011 | Acute Lymphobla... | - | Sheba Medical Center | ||
| Allogeneic T Cells Expressing T Cell Receptor-KDEL and the Chimeric Antigen Receptor CAT19 for the Treatment of Advanced CD19+ Malignancies | NCT05391490 | Blood Cancer | KCAT19 T cells | 16 Years - 65 Years | University College, London | |
| CTL019 Out of Specification MAP for ALL or DLBCL Patients | NCT03601442 | Acute Lymphobla... Diffuse Large B... | CTL019 | 1 Day - 25 Years | Novartis | |
| Study Evaluating the Safety and Efficacy of JCARH125 in Subjects With Relapsed and/or Refractory Multiple Myeloma | NCT03430011 | Multiple Myelom... | JCARH125 JCARH125 + anak... | 18 Years - | Juno Therapeutics, a Subsidiary of Celgene | |
| Mesothelin-targeted CAR T-cell Therapy in Patients With Mesothelioma | NCT04577326 | Malignant Pleur... | cyclophosphamid... CAR T cells | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Study of Feasibility and Safety of UCD19 Chimeric Antigen Receptor (CAR) T Cells in Adult Subjects With Relapsed/Refractory (R/R) B-Cell Non-Hodgkin's Lymphoma (B-NHL) | NCT04240808 | Non Hodgkin Lym... | UCD19 CAR T Cel... | 18 Years - 80 Years | University of Colorado, Denver | |
| CD147-CAR T Cells for Relapsed/Refractory T Cell Non-Hodgkin's Lymphoma | NCT05013372 | T-cell Non-Hodg... | CD147- CAR T ce... | 18 Years - 65 Years | Peking University People's Hospital | |
| CD147-CAR T Cells for Relapsed/Refractory T Cell Non-Hodgkin's Lymphoma | NCT05013372 | T-cell Non-Hodg... | CD147- CAR T ce... | 18 Years - 65 Years | Peking University People's Hospital | |
| Study of αPD1-MSLN-CAR T Cells to Evaluate the Safety, Tolerability, and Effectiveness for Patients With MSLN-positive Advanced Solid Tumors | NCT05089266 | Colorectal Canc... | CAR T cells | 18 Years - 70 Years | Shanghai Cell Therapy Group Co.,Ltd | |
| A Safety and Efficacy Trial of JCAR017 Combinations in Subjects With Relapsed/Refractory B-cell Malignancies | NCT03310619 | Lymphoma, Non-H... Lymphoma, Large... Lymphoma, Folli... | JCAR017 Durvalumab CC-122 Ibrutinib CC-220 Relatlimab Nivolumab CC-99282 | 18 Years - | Celgene | |
| Malignant Pleural Disease Treated With Autologous T Cells Genetically Engineered to Target the Cancer-Cell Surface Antigen Mesothelin | NCT02414269 | Malignant Pleur... Mesothelioma Metastases Lung Cancer Breast Cancer | iCasp9M28z T ce... cyclophosphamid... pembrolizumab | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Allogeneic T Cells Expressing T Cell Receptor-KDEL and the Chimeric Antigen Receptor CAT19 for the Treatment of Advanced CD19+ Malignancies | NCT05391490 | Blood Cancer | KCAT19 T cells | 16 Years - 65 Years | University College, London | |
| Anti-CD19 CAR-T Cells With Inducible Caspase 9 Safety Switch for B-cell Lymphoma | NCT03696784 | Lymphoma Lymphoma, B-Cel... Immune System D... Immunoprolifera... Lymphatic Disea... | iC9-CAR19 T cel... Bendamustine Fludarabine AP1903 Cyclophosphamid... | 18 Years - | UNC Lineberger Comprehensive Cancer Center | |
| Study of ATLCAR.CD138 Cells for Relapsed/Refractory Multiple Myeloma | NCT03672318 | Multiple Myelom... Immune System D... | CAR138 T Cells | 18 Years - | UNC Lineberger Comprehensive Cancer Center | |
| Study of CD30 CAR for Relapsed/Refractory CD30+ HL and CD30+ NHL | NCT02690545 | Lymphoma Lymphoma, Non-H... Immune System D... Immunoprolifera... Lymphatic Disea... Lymphoprolifera... Neoplasms Neoplasms by Hi... | ATLCAR.CD30 cel... | 3 Years - | UNC Lineberger Comprehensive Cancer Center | |
| Anti-CD19 CAR-T Cells With Inducible Caspase 9 Safety Switch for B-cell Lymphoma | NCT03696784 | Lymphoma Lymphoma, B-Cel... Immune System D... Immunoprolifera... Lymphatic Disea... | iC9-CAR19 T cel... Bendamustine Fludarabine AP1903 Cyclophosphamid... | 18 Years - | UNC Lineberger Comprehensive Cancer Center | |
| Administration of Autologous CAR-T CD19 Antigen With Inducible Safety Switch in Patients With Relapsed/Refractory ALL | NCT03016377 | Acute Lymphobla... Immune System D... Immunoprolifera... | iC9-CAR19 cells Rimiducid Cyclophosphamid... Fludarabine | 3 Years - 70 Years | UNC Lineberger Comprehensive Cancer Center | |
| Study of Efficacy and Safety of CRC01 in Adult Large B-cell Lymphoma Patients | NCT04836507 | Relapsed Large ... Refractory Larg... Diffuse Large B... Primary Mediast... High-grade B-ce... Transformed Fol... | CRC01 Fludarabine Cyclophosphamid... | 19 Years - | Curocell Inc. | |
| Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (TRANSCEND-NHL-001) | NCT02631044 | Non-Hodgkin Lym... Diffuse Large B... Follicular Lymp... Mantle-cell Lym... Primary Mediast... | JCAR017 (lisoca... JCAR017 (lisoca... | 18 Years - | Juno Therapeutics, a Subsidiary of Celgene | |
| CAR T Cells to Target GD2 for DMG | NCT05544526 | Diffuse Midline... | GD2 CAR T cells | - 16 Years | University College, London | |
| Autologous CD22 CAR T Cells in Adults w/ Recurrent or Refractory B Cell Malignancies | NCT04088890 | B-ALL B-cell Non Hodg... DLBCL Follicular Lymp... | Fludarabine Cyclophosphamid... CD22 CAR | 18 Years - | Stanford University | |
| CTL019 Out of Specification MAP for ALL or DLBCL Patients | NCT03601442 | Acute Lymphobla... Diffuse Large B... | CTL019 | 1 Day - 25 Years | Novartis | |
| Multi-modular Chimeric Antigen Receptor Targeting GD2 in Neuroblastoma | NCT05990751 | Neuroblastoma | GD2 CAR T cells | 1 Year - 16 Years | University College, London | |
| A Study of MCARH109 and MCARH125 in People With Multiple Myeloma | NCT05431608 | Multiple Myelom... Refractory Mult... Relapse Multipl... | MCARH125 MCARH109 | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| CD147-CAR T Cells for Relapsed/Refractory T Cell Non-Hodgkin's Lymphoma | NCT05013372 | T-cell Non-Hodg... | CD147- CAR T ce... | 18 Years - 65 Years | Peking University People's Hospital | |
| Efficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma Patients | NCT04844866 | Diffuse Large B... | MB-CART2019.1 R-GemOx or BR p... | 18 Years - | Miltenyi Biomedicine GmbH | |
| Vaccine Responsiveness After CAR-T Cell Therapy | NCT04410900 | B-Cell Neoplasm | Wistar Rabies V... Biospecimen Col... | 18 Years - | Fred Hutchinson Cancer Center | |
| Administration of T Lymphocytes for Prevention of Relapse of Lymphomas | NCT02663297 | Hodgkin Disease Lymphoma Lymphoma, Non-H... Immune System D... Immunoprolifera... Lymphatic Disea... Lymphoprolifera... Neoplasms Neoplasms by Hi... | ATLCAR.CD30 cel... | 3 Years - | UNC Lineberger Comprehensive Cancer Center | |
| Study of Kappa Chimeric Antigen Receptor (CAR) T Lymphocytes Co-Expressing the Kappa and CD28 CARs for Relapsed/Refractory Kappa+ Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. | NCT04223765 | Mantle Cell Lym... Follicular Lymp... Splenic Margina... Extranodal Marg... Nodal Marginal ... Indolent Non-ho... | CAR.k.28 Fludarabine Cyclophosphamid... Bendamustine | 18 Years - | UNC Lineberger Comprehensive Cancer Center | |
| Autologous CD22 CAR T Cells in Adults w/ Recurrent or Refractory B Cell Malignancies | NCT04088890 | B-ALL B-cell Non Hodg... DLBCL Follicular Lymp... | Fludarabine Cyclophosphamid... CD22 CAR | 18 Years - | Stanford University | |
| CD19-targeting CAR T Cells for B Cell Lymphoma | NCT02547948 | B Cell Lymphoma | CD19-targeting ... | 18 Years - 80 Years | Fuda Cancer Hospital, Guangzhou | |
| Study of Feasibility and Safety of UCD19 Chimeric Antigen Receptor (CAR) T Cells in Adult Subjects With Relapsed/Refractory (R/R) B-Cell Non-Hodgkin's Lymphoma (B-NHL) | NCT04240808 | Non Hodgkin Lym... | UCD19 CAR T Cel... | 18 Years - 80 Years | University of Colorado, Denver | |
| Donor-Derived Anti-CD33 CAR T Cell Therapy (VCAR33) in Patients With Relapsed or Refractory AML After Allogeneic Hematopoietic Cell Transplant | NCT05984199 | Leukemia, Myelo... | VCAR33 | 18 Years - | Vor Biopharma | |
| CD30 CAR T Cells, Relapsed CD30 Expressing Lymphoma (RELY-30) | NCT02917083 | Hodgkin's Lymph... Non-Hodgkin Lym... | CAR T Cells | 12 Years - 75 Years | Baylor College of Medicine |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
